Home
 
Login  
About Hospital Safety Center  
Career Center  
Contact Us
 
Subscribe  
       Free Resources
Hospital Safety Insider
E-Newsletter

 
Mac's Safety Space  
        News & Analysis
Healthcare Safety Leader  
Environment of Care Leader  
Forms and Checklists Library  

 

 

     
This is an excerpt from a member-only article. To read the article in its entirety, please login or subscribe.

NIOSH seeks to separate handling guidance from list of hazardous drugs

EMAIL THIS STORY | PRINT THIS STORY | SUBSCRIBE | ARCHIVES

July 18, 2020

by A.J. Plunkett (aplunkett@decisionhealth.com)

The CDC’s National Institute for Occupational Safety and Health (NIOSH) is proposing to separate out and expand guidance for healthcare facilities on the handling of hazardous drugs.

The proposal is part of a long-awaited update to the “NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings,” which has not been updated since 2016. An update proposed for 2018 never materialized.

The newest proposal was published in the Federal Register on May 1, with a request for public comments through June 30.

The proposed rule includes a name change and reorganization of drug lists so that not all antineoplastic drugs, most often associated with cancer treatments, are grouped together. The list would be more simply the “NIOSH List of Hazardous Drugs in Healthcare Settings, 2020.”

The newest proposal was published in the Federal Register on May 1, with a request for public comments through June 30.



This is an excerpt from a member-only article. To read the article in its entirety, please login or subscribe.

Subscribe Now!
Sign up for our free e-newsletter
About Us | Terms of Use | Privacy Statement | Contact Us
Copyright © 2020. Hospital Safety Center.